Louisiana's peptide law, Act 374, takes effect August 1, 2026

Louisiana Act 374 bars state licensing boards from prohibiting peptide prescribing and compounding that comply with federal 503A or 503B law, and this sets out its text and limits.

Basics4 min read

Key takeaway

Since August 1, 2026, no Louisiana professional or occupational licensing board may prohibit a prescriber from providing patients with peptides shipped from a compliant 503B outsourcing facility or 503A compounding pharmacy. Boards also may not prohibit a Louisiana pharmacist in a state-permitted pharmacy from compounding and dispensing peptides. Each protection depends on compliance with federal compounding law.

At a glance

Article typeBasics
TopicLaw & regulation
Studies cited0
Related productsResearch peptide catalog

A new Louisiana peptide law took effect on August 1, 2026. Act 374 of the 2026 Regular Session, passed as Senate Bill 253 and signed by the governor on May 22, 2026, adds section 37:23.5 to the Louisiana Revised Statutes, titled “Peptides; prohibited regulations.” It limits what the state’s licensing boards can do about peptides. This article sets out the text, from records checked on November 17, 2026.

Quick answer: Does Act 374 make peptides legal to sell in Louisiana? Not in general. It limits state licensing boards, and only where the pharmacy or outsourcing facility complies with federal compounding law. It does not approve any peptide, change FDA rules or mention peptides sold for laboratory research.

This article summarizes public records. It is not legal advice.

What does Act 374 say?

The Act has two parts (Louisiana Legislature, 2026a). Subsection A says no licensing board shall prohibit “a healthcare provider with prescriptive authority from providing patients with peptides” shipped from either of two sources. Subsection B protects pharmacists who compound and dispense peptides. Table 1 shows the conditions.

Table 1

What R.S. 37:23.5 protects, and on what condition

Subsection Who is protected from a board ban Condition in the Act
A(1) Prescribers providing peptides shipped from a 503B outsourcing facility FDA-registered and in compliance with 21 U.S.C. 353b
A(2) Prescribers providing peptides shipped from a 503A compounding pharmacy In compliance with 21 U.S.C. 353a and applicable USP-NF chapters
B Louisiana-licensed pharmacists in a state-permitted pharmacy compounding and dispensing peptides In compliance with 21 U.S.C. 353a and applicable USP-NF chapters

The Louisiana Board of Pharmacy summarized the Act for licensees in Bulletin 26-01, dated July 10, 2026. It describes the Act as providing that no licensing board shall prohibit a pharmacist from compounding and dispensing peptides “if the pharmacist complies with 21 USC 353a (503A) and applicable USP-NF chapters” (Louisiana Board of Pharmacy, 2026).

What does it change, and what does it not change?

It changes the power of Louisiana’s licensing boards. No professional or occupational licensing board in the state may prohibit the conduct in Table 1 when its conditions are met.

It does not change federal law, and its conditions point back to it. Sections 353a and 353b of Title 21 are the federal 503A and 503B compounding provisions. FDA says a 503A pharmacy may use a bulk drug substance only if it meets a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA’s 503A bulks list (FDA, 2026). The Act also does not:

  • define “peptides” or name any peptide;
  • approve any product or make one available;
  • say anything about peptides sold for laboratory research.

Research-grade peptides, like those in our catalog, are sold for laboratory research use only, not for human or veterinary use. They are not compounded or prescribed products.

Who does it affect?

Licensing boards: any professional or occupational board in Louisiana. Prescribers: healthcare providers with prescriptive authority. Pharmacists: Louisiana-licensed pharmacists in state-permitted pharmacies. Compounders: compliant 503A pharmacies and FDA-registered 503B outsourcing facilities, as the sources named in subsection A. Sellers and researchers: not addressed.

What happens next?

The Act is in force with no later dates in its text. Its reach depends on what counts as compliance with section 503A or 503B. On October 30, 2026, HHS published a draft, non-binding policy saying it does not intend to take enforcement action against certain 503A compounders using peptides listed in the policy’s Appendix A (HHS, 2026). Act 374 predates that notice and does not mention it.

Table 2

Act 374 timeline

Date Event
May 7, 2026 House final passage, 98 yeas, 0 nays
May 18, 2026 Senate concurs in House amendments, 37 yeas, 0 nays
May 22, 2026 Signed by the governor; becomes Act 374
July 10, 2026 Board of Pharmacy Bulletin 26-01 summarizes the Act
August 1, 2026 Act 374 takes effect

How does it fit the earlier history?

Senator Patrick McMath authored SB 253, with Representatives Bayham, Berault, Carver and Wyble (Louisiana Legislature, 2026b). The House passed it 98 to 0, and the Senate concurred in the House amendments 37 to 0. The federal background is in our explainers on 503A versus 503B compounding, the 503A categories and peptides and the FDA in 2026. Our page on whether peptides are legal in the USA covers the wider picture.

Frequently asked questions about Louisiana Act 374

When did the Louisiana peptide law take effect?

August 1, 2026. It was signed on May 22, 2026.

Which peptides does it cover?

It does not list or define any. It refers only to “peptides.”

Does it override federal compounding rules?

No. Each protection depends on compliance with 21 U.S.C. 353a or 353b, the federal 503A and 503B provisions.

Does it cover research-use-only peptides?

No. The Act addresses prescribers, pharmacists and compounding. It does not mention research chemical sales.

What to know now

  • Law: Louisiana Act 374 (SB 253), R.S. 37:23.5, effective August 1, 2026.
  • Effect: licensing boards may not prohibit compliant peptide prescribing or compounding.
  • Condition: compliance with federal 503A or 503B law and, for 503A, USP-NF chapters.
  • Not changed: FDA approval status, federal compounding rules, research-use sales.

What we’re watching

Any Louisiana board rules or guidance that respond to the Act. A final version of the HHS peptide compounding policy. And similar bills in other states.

Also in the library

Sources: Louisiana Legislature 2026a; Louisiana Legislature 2026b, SB253, 2026 Regular Session: bill information and history; Louisiana Board of Pharmacy 2026, Bulletin No. 26-01: Legislative update, 2026 Regular Session; U.S. Food and Drug Administration 2026, Bulk drug substances used in compounding under section 503A of the FD&C Act; Office of the Secretary 2026, Federal Register, 91. All 5 citations

Back to the research library

References

  1. Louisiana Legislature. (2026a). Act No. 374 (Senate Bill No. 253), 2026 Regular Session, enrolled: R.S. 37:23.5, peptides; prohibited regulations. https://legis.la.gov/legis/ViewDocument.aspx?d=1478374
  2. Louisiana Legislature. (2026b). SB253, 2026 Regular Session: bill information and history. Retrieved November 17, 2026, from https://legis.la.gov/legis/BillInfo.aspx?s=26RS&b=SB253&sbi=y
  3. Louisiana Board of Pharmacy. (2026, July 10). Bulletin No. 26-01: Legislative update, 2026 Regular Session. https://www.pharmacy.la.gov/assets/docs/Bulletins/Bulletin_26-01_NewLaws_2026RS_2026-0710.pdf
  4. U.S. Food and Drug Administration. (2026). Bulk drug substances used in compounding under section 503A of the FD&C Act (content current as of May 14, 2026). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  5. Office of the Secretary, U.S. Department of Health and Human Services. (2026, October 30). Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances; notice of availability (FR Doc. 2026-22192). Federal Register, 91, 68526. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances